Medtronic plc stock holds near USD 91 as investors weigh recent growth signals

Published on 09/14/2026 at 11:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic plc stock closed at USD 90.96 on September 11, 2026, roughly 12 percent below its 52-week high. Recent commentary highlights moderate earnings growth and an improving outlook for key product lines.

Reinraumfertigung mit Technikern bei Montage medizintechnischer Präzisionsinstrumente — Medtronic plc (ISIN IE00BTN1Y115) Reinraum-Fertigung zeigt Techniker bei der Montage medizinischer Präzisionsinstrumente sorgfältig, Illustration mit AI erstellt.

Medtronic plc stock (ISIN IE00BTN1Y115) closed at USD 90.96 on the New York Stock Exchange on September 11, 2026, leaving the medical device maker trading meaningfully below its recent 52-week high while investors reassess its growth prospects and income profile.

Share price and recent performance

According to data from a major US stock portal, Medtronic plc stock ended regular trading at USD 90.96 on September 11, 2026, down 0.66 dollars or 0.72 percent from the prior close, with an after-hours indication at USD 91.22 later that day. The same overview shows that the shares were at USD 96.13 on January 1, 2026, meaning the stock has declined about 5.4 percent year to date as of mid-September 2026.

One recent comparative analysis notes that Medtronic trades at a trailing price-to-earnings ratio of 23 and a forward P/E of 15, with the shares at around USD 90.98 on mid-September 2026, down 3.69 percent since the start of the year and below a 52-week high of USD 103.76. As of that snapshot, the stock therefore sits roughly 12 percent under its 52-week peak, a level that can matter for investors who watch valuation against recent highs.

Earnings and growth signals

An earnings calendar entry for September 14, 2026 highlights that Medtronic’s latest reported quarter saw both earnings per share and revenue come in above consensus estimates, underscoring that the company managed to beat expectations in its most recent set of results. While exact figures are not detailed in that snippet, the classification that Q1 earnings and revenues topped estimates indicates at least moderate upside relative to what analysts had forecast for that period.

Sector commentary puts these numbers into a broader context by pointing out that Medtronic shares have fallen by about 30 percent over the past five years, even as the company remains one of the world’s largest medical device manufacturers. This divergence between long-term share performance and the underlying scale of the business is part of why some market observers now frame Medtronic as a potential value and income candidate rather than a high-growth story.

Valuation and dividend perspective

A mid-September 2026 comparison of major medical device dividend payers highlights Medtronic as an attractive option for retirement-focused income investors when set against a close peer. In that assessment, Medtronic’s combination of a forward P/E around 15, a share price near USD 90.98, and a multi-decade record of dividend payments is presented as relatively compelling. The same piece stresses that for investors buying Medtronic plc stock at current levels, the starting valuation is not excessive compared with the sector, particularly given the company’s global footprint in cardiology, surgery and diabetes technologies.

Dividend overviews show that Medtronic’s previous ex-dividend date for a cash distribution of USD 0.71 per share was in late September 2025, with payment in October 2025. While this dividend history is now historical relative to September 2026, it underlines the company’s pattern of regular quarterly distributions that income investors may consider alongside earnings trends.

Product lines and innovation backdrop

Recent sector coverage on minimally invasive and AI-supported procedures notes that at Medtronic’s fiscal year 2026 second-quarter earnings meeting, management highlighted that its Endoscopy and Esophageal business line recorded overall growth of 8 percent. Within that unit, an AI-assisted endoscopy platform referred to as GI Genius was described as delivering strong double-digit revenue growth and contributing to colonoscopy hardware momentum. For investors, these growth points in specific segments can help explain why earnings have been able to modestly surpass expectations even as the broader share price has lagged over longer horizons.

At the same time, broader commentary from outlets tracking Medtronic’s share performance emphasizes that the stock’s roughly 30 percent decline over five years remains a risk factor. It suggests that repeated execution challenges and slower-than-hoped growth in certain product categories have weighed on sentiment, even if current earnings beats and select segment growth provide some counterbalance.

Medtronic plc stock and current trading level

With Medtronic plc stock at USD 90.96 as of the September 11, 2026 close on the New York Stock Exchange, the shares are trading below both their 52-week high of USD 103.76 and their level at the start of 2026, but above the 52-week low referenced in recent valuation summaries. For investors, the current price zone combines a moderate discount to the high with a valuation near 15 times forward earnings, a mix that keeps attention on whether upcoming quarters can sustain earnings beats and segment growth.